You are here

Share:

Human Monoclonal Antibodies Against Dengue Viruses

Summary
Researchers at NCI's  Cancer and Inflammation Program developed fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses. The National Cancer Institute's Cancer and Inflammation Program seeks parties interested in licensing fully human monoclonal antibodies as possible therapeutics and prophylactics, as well as a template for a Dengue vaccine.
NIH Reference Number
E-273-2011
Product Type
Keywords
  • dengue
  • hemorrhagic fever
  • immunization
  • Dimitrov
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

Dengue viruses cause dengue outbreaks and major epidemics in most tropical and subtropical areas where Aedes albopictus and Aedes aegypti mosquitoes are abundant. Among the arthropod-borne flaviviruses, the four dengue virus serotypes, dengue type 1 virus (DENV-1), dengue type 2 virus (DENV-2), dengue type 3 virus (DENV-3), and dengue type 4 virus (DENV-4) are most important in terms of human morbidity and geographic distribution.

A safe and effective vaccine against dengue is currently not available. Passive immunization with monoclonal antibodies from non-human primates or humans represents a possible alternative to vaccines for prevention of illness caused by dengue virus.  Researchers at NCI's  Cancer and Inflammation Program developed fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses, as well as fragments of such antibodies and nucleic acids encoding the antibodies of the technology, and prophylactic, therapeutic and diagnostic methods employing the antibodies and nucleic acids of the invention.

Potential Commercial Applications
  • Prophylaxis/therapy against dengue serotypes 1, 2, 3, and 4;
  • Dengue diagnostics.
Competitive Advantages
  • Antibodies are cross-reactive with all four serotypes of dengue;
  • Antibodies are fully human.
Inventor(s)

Dimiter S. Dimitrov (NCI), Zhongyu Zhu (NCI)

Development Stage
Publications

V. Puri et al. [PMID: 23765162]

Patent Status
  • U.S. Patent Issued: U.S. Patent Number 9556254, Filed 12 Nov 2014, Issued 31 Jan 2017
Related Technologies
  • E-066-2003
Therapeutic Area
Updated
Tuesday, November 14, 2017